<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200127046280N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-10-17</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>The Comparative evaluation of effect of Sublingual Misoprostol versus cervical misoprostol on second Trimester abortions</public_title>
      <acronym></acronym>
      <scientific_title>The comparative evaluation of the effect of sublingual misoprostol versus  wet cervical misoprostol on duration of abortion in patients candidates for  abortion in early second Trimester</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45664</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who meet the inclusion criteria are divided into two intervention groups using simple randomization method.The randomization method used in this study is the use of a table of random numbers.Random number table is a set of numbers that is generated without a specific pattern or order and they generated randomly and they are formed in a table.In first the direction of reading the numbers was specified.To read the numbers, random numbers are read from the left side of the table, then even numbers extracted from the table are allocated to intervention group a and odd numbers extracted from the table are allocated to intervention group b, Blinding description: Participants are unaware of treatment allocation and are divided into groups a and b. Group a receives sublingual misoprostol with cervical placebo and group b receives cervical misoprostol with sublingual placebo. Finally, the results of the work are filled by the midwife of the ward, using the questionnaire form and provided to the researcher.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Abortion.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group (group a): This group will receive 200 mcg of sublingual misoprostol from the brand (Cytotec, Searle, England) along with cervical placebo(alborz daroo company) and then the mentioned dose will be repeated every 4 hours until the abortion.The maximum duration of drug administration will be up to 48 hours. Intervention 2: Intervention group 2 (group b): This group will receive 200 mcg of cervical misoprostol from brand (Cytotec, Searle, England) moistened with a few drops of distilled water along with sublingual placebo(alborz daroo company) and then the mentioned dose is repeated every 4 hours until abortion. The maximum duration of drug administration will be up to 48 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A part of the data, such as information about the main outcome, can be shared.

When:
Access period starts 6 months after publishing the results.

To whom:
It will be available only to researchers working in academic and scientific institutions

Conditions:
If another similar clinical trial is performed

Where to obtain:
Email

How to obtain:
After receiving the email and the proposal and ensuring that the information is not misused

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoumeh Dadashaliha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, Bahar Doctors Building ,East Bouali St.</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3491658875</zip>
        <telephone>+98 28 3322 9304</telephone>
        <email>dadashaliham@yahoo.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoumeh Dadashaliha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 2, Bahar Doctors Building ,East Bouali St.</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3491658875</zip>
        <telephone>+98 28 3322 9304</telephone>
        <email>dadashaliham@yahoo.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Unifetal pregnancy
Missed abortion
Fetal malformations
Blighted ovum
Trisomies
Gestational age ( 12 weeks and less than 12 weeks )</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Rupture of membrane
History of cesarean section more than once
History of allergy to misoprostol and prostaglandins
Contraindications of prostaglandin use ( like heart disease, kidney disease, history of seizures and hypotension )</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O02.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Missed abortion</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group (group a): This group will receive 200 mcg of sublingual misoprostol from the brand (Cytotec, Searle, England) along with cervical placebo(alborz daroo company) and then the mentioned dose will be repeated every 4 hours until the abortion.The maximum duration of drug administration will be up to 48 hours.</i_keyword>
      <i_keyword>Intervention group 2 (group b): This group will receive 200 mcg of cervical misoprostol from brand (Cytotec, Searle, England) moistened with a few drops of distilled water along with sublingual placebo(alborz daroo company) and then the mentioned dose is repeated every 4 hours until abortion. The maximum duration of drug administration will be up to 48 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The time interval between induction of abortion and excretion of pregnancy products. Timepoint: After intervention and then every one hour. Method of measurement: clock.</prim_outcome>
      <prim_outcome>Nausea (drug side effects). Timepoint: After intervention and then every one hour. Method of measurement: Clinical examination and questioning of the patient.</prim_outcome>
      <prim_outcome>Vomiting (drug side effects). Timepoint: After intervention and then every one hour. Method of measurement: Clinical examination and questioning of the patient.</prim_outcome>
      <prim_outcome>Fever (drug side effects). Timepoint: After intervention and then every one hour. Method of measurement: Thermometer.</prim_outcome>
      <prim_outcome>Diarrhea (drug side effects). Timepoint: After intervention and then every one hour. Method of measurement: Clinical examination and questioning of the patient.</prim_outcome>
      <prim_outcome>Headache (drug side effects). Timepoint: After intervention and then every one hour. Method of measurement: Clinical examination and questioning of the patient.</prim_outcome>
      <prim_outcome>Abortion type (Complete or incomplete). Timepoint: After intervention and then every one hour. Method of measurement: Clinical examination with speculum and doing ultrasonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-25</approval_date>
        <contact_name>Ethics committee of Qazvin University Of Medical Science</contact_name>
        <contact_address>No 4, mavedat ave, shahid beheshti blvd Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
